Preemptive treatment with Panitumumab helps in curbing skin toxicitySome of the skin-associated toxicities that occur in patients receiving panitumumab for treatment of metastatic colorectal cancer may be avoided with a preemptive, prophylactic skin regimen.

This finding was disclosed in data presented at the 2009 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco.

Edith Mitchell, M.D., a clinical professor in the Department of Medical Oncology at Jefferson Medical College of Thomas Jefferson University, presented data from the study, which was co-led by Dr. Mitchell and Mario Lacouture, M.D., an assistant professor of Dermatology at Northwestern University’s Feinberg School of Medicine in Chicago.